Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name FGFR2 - SHTN1
Gene Variant Detail

FGFR2 - SHTN1 (gain of function - predicted)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 - SHTN1 Advanced Solid Tumor predicted - sensitive E7090 Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2-SHTN1 were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 - SHTN1 Advanced Solid Tumor predicted - sensitive Infigratinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2-SHTN1 were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 - SHTN1 Advanced Solid Tumor resistant Dovitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FGFR2-SHTN1 demonstrated resistance to treatment with Dovitinib (TKI258) in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 Advanced Solid Tumor sensitive Futibatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with Futibatinib (TAS-120), demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 Advanced Solid Tumor sensitive Erdafitinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2-SHTN1 were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 - SHTN1 Advanced Solid Tumor sensitive Erdafitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with Balversa (erdafitinib), demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 cholangiocarcinoma sensitive Futibatinib Preclinical - Cell culture Actionable In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with Futibatinib (TAS-120), demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 Advanced Solid Tumor predicted - sensitive Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FGFR2-SHTN1 were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). 34272467
FGFR2 - SHTN1 cholangiocarcinoma sensitive Erdafitinib Preclinical - Cell culture Actionable In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with Balversa (erdafitinib), demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 Advanced Solid Tumor sensitive AZD4547 Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with AZD4547, demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 Advanced Solid Tumor sensitive Ponatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FGFR2-SHTN1 were sensitive to treatment with Iclusig (ponatinib), demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 cholangiocarcinoma predicted - sensitive Infigratinib Case Reports/Case Series Actionable In a Phase II trial, a patient with cholangiocarcinoma harboring FGFR2-SHTN1 experienced a partial response according to RECIST criteria after four months of treatment with Truseltiq (infigratinib) (PMID: 31911531). 31911531
FGFR2 - SHTN1 cholangiocarcinoma resistant Dovitinib Preclinical - Cell culture Actionable In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 demonstrated resistance to treatment with Dovitinib (TKI258) in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 cholangiocarcinoma sensitive Ponatinib Preclinical - Cell culture Actionable In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with Iclusig (ponatinib), demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
FGFR2 - SHTN1 cholangiocarcinoma sensitive AZD4547 Preclinical - Cell culture Actionable In a preclinical study, cholangiocarcinoma cells expressing FGFR2-SHTN1 were sensitive to treatment with AZD4547, demonstrating decreased cell viability in culture (PMID: 31911531). 31911531
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries